Mandate

Vinge advises Taiyo Nippon Sanso corporation and Matheson Tri-Gas on the acquisition of the swedish part of Praxair’s european industrial gas business

July 10, 2018 M&A

Vinge advises Japanese industrial gas producer Taiyo Nippon Sanso Corporation (TNSC) and its subsidiary Matheson Tri-Gas (MTG) on the acquisition of the Swedish part of Praxair's European industrial gas business.

The transaction expands TNSC's global presence and represents its entry into the European market. The purchase price for Praxair's European industrial gas business amounts to approximately EUR 5 billion.

The transaction is subject to the successful completion of the Praxair and Linde merger and the fulfilment of antitrust conditions. In order to obtain the approval of the European Commission and the U.S. Federal Trade Commission, Linde and Praxair have to sell European and non-European assets. Praxair will continue to operate these businesses until the completion of the merger. The transaction is expected to close in the second half of 2018.

Vinge’s team consists of Matthias Pannier together with associates Karl Klackenberg, Carl Sander and Boris Kotur. 
 

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025